{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:19:58Z","timestamp":1792153198293,"version":"4.4.0"},"reference-count":74,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The global prevalence of multiple sclerosis (MS) is increasing, and early diagnosis and treatment is essential in mitigating disability. While recent therapeutic advancements have significantly reduced relapse rates, the progressive and degenerative aspects of MS continue to pose major challenges. This year updates to the McDonald diagnostic criteria aim to enhance sensitivity and facilitate earlier use of disease\u2010modifying therapies in asymptomatic patients. Additionally, novel biomarkers will gain ground in clinical practice and offer new approaches to optimising care. Following the widespread use of cell depleting immunosuppressive agents, innovative therapeutic directions such as chimeric antigen receptor T\u2010cell therapy and Epstein\u2013Barr virus (EBV) vaccination represent promising new directions in the management of MS. This clinical perspective provides a comprehensive overview of the disease while highlighting important advancements shaping the future of the field.<\/jats:p>","DOI":"10.1111\/imj.70023","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:02:32Z","timestamp":1743742952000},"page":"895-904","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Advancements in multiple sclerosis"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4756-1756","authenticated-orcid":false,"given":"Turlough","family":"Montague","sequence":"first","affiliation":[{"name":"Department of Neurology Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Drummond","sequence":"additional","affiliation":[{"name":"Brain Imaging Laboratory, Department of Radiation Oncology Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-3773","authenticated-orcid":false,"given":"Karl","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal North Shore Hospital  Sydney New South Wales Australia"},{"name":"Northern Clinical School University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Parratt","sequence":"additional","affiliation":[{"name":"Department of Neurology Royal North Shore Hospital  Sydney New South Wales Australia"},{"name":"Northern Clinical School University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.100977","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"48","author":"Portaccio E","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0080456800027174"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39770-1"},{"key":"e_1_2_11_5_1","volume-title":"An Interim Update of Prevalence, Costs and Cost of Illness from 2017 to 2021","author":"Campbell J","year":"2021"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208051","article-title":"Clinical characteristics and long\u2010term outcomes of late\u2010onset multiple sclerosis: a Swedish nationwide study","volume":"102","author":"Mouresan EF","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00556-y"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104696"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241245318","article-title":"Prevalence and incidence of multiple sclerosis in Turkey: a nationwide epidemiologic study","volume":"30","author":"Ozturk B","year":"2024","journal-title":"Mult Scler J"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/614716"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105786"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.835162"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028944"},{"key":"e_1_2_11_15_1","first-page":"S134\u2013","article-title":"Multiple sclerosis in time and space \u2013 geographic clues to cause","volume":"6","author":"Kurtzke JF","year":"2000","journal-title":"J Neurovirol"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209350","article-title":"Proportion of life spent in Canada and the incidence of multiple sclerosis in permanent immigrants","volume":"102","author":"Vyas MV","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12428"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519861270"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0086-4"},{"key":"e_1_2_11_20_1","unstructured":"ThouvenotE LaplaudD Lebrun\u2010FrenayC et al.High\u2010dose cholecalciferol reduces multiple sclerosis disease activity after a clinically isolated syndrome: results of a 24\u2010month placebo\u2010controlled randomized trial (D\u2010lay MS). Presented at: ECTRIMS 2024; 2024. Abstract Number: 1291\/O065."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8222"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212676"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.11.003"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00770-5"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1451"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt139"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2014.01.002"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028951"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00255-1"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06618-z"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e24124"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/969657"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(02)00426-4"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11193-w"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlab083"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.01.021"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm038"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103555"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27034"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612631"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207936"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1583"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0292"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1177oa"},{"key":"e_1_2_11_46_1","first-page":"2058","article-title":"Fatigue in multiple sclerosis is associated with reduced expression of interleukin\u201010 and worse prospective disease activity","volume":"10","author":"Gilio L","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12173-4"},{"key":"e_1_2_11_48_1","volume-title":"Presented at ECTRIMS Congress; September 18\u201320, 2024","author":"Montalban X","year":"2024"},{"key":"e_1_2_11_49_1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.21037\/atm-21-3073","article-title":"Application of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review","volume":"11","author":"Jin H","year":"2023","journal-title":"Ann Transl Med"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25799"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz144"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256845"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14111120"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.004"},{"key":"e_1_2_11_55_1","article-title":"Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis","volume":"5","author":"Filippini G","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_56_1","article-title":"Efficacy and tolerability of prucalopride in patients with constipation due to multiple sclerosis: a double\u2010blind placebo\u2010controlled pilot study","volume":"45","author":"Medaer R","year":"1999","journal-title":"Gut"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12010006"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00549-7"},{"key":"e_1_2_11_59_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2\u2009years in a Norwegian population\u2010based registry","volume":"17","author":"Simonsen CS","year":"2021","journal-title":"Front Neurol"},{"key":"e_1_2_11_60_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/13524585231213230","article-title":"The disease\u2010modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022","volume":"30","author":"Zhao T","year":"2024","journal-title":"Mult Scler"},{"key":"e_1_2_11_61_1","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1212\/WNL.0000000000205584","article-title":"10\u2009years of ocrelizumab treatment in multiple sclerosis: Long\u2010Term efficacy and safety clinical trial data (S31.005)","volume":"102","author":"Hauser S","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104701"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004354"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-023-01290-2"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332790"},{"key":"e_1_2_11_66_1","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.654942","article-title":"Serum neurofilament light chain measurement in MS: hurdles to clinical translation","volume":"25","author":"Thebault S","year":"2021","journal-title":"Front Neurosci"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14070692"},{"key":"e_1_2_11_68_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/WNL.0000000000205905","article-title":"Changes in plasma NfL and GFAP in response to anti\u2010CD20 treatment in MS (P9\u20106.013)","volume":"102","author":"Gross R","year":"2024","journal-title":"Neurology"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0017"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00800-7"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00328-4"},{"key":"e_1_2_11_72_1","unstructured":"Sanofi.Sanofi Unveils Press Release. [cited 2024 Sep 2] Available from URL:https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-09-02-05-00-00-2938875."},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.03.002"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309439"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1231363100"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:05:16Z","timestamp":1749643516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/imj.70023"],"URL":"https:\/\/doi.org\/10.1111\/imj.70023","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"2025-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}